Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Author's Avatar
Aug 13, 2021
  • Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies
  • Strong royalty growth with PolyXen® platform technology
  • Bolstered cash position with recently completed $12.5 million private placement